Efficacy and safety analysis of monthly minodronic acid in Japanese osteoporotic patients switched from traditional bisphosphonates

Trial Profile

Efficacy and safety analysis of monthly minodronic acid in Japanese osteoporotic patients switched from traditional bisphosphonates

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 May 2016

At a glance

  • Drugs Minodronic acid (Primary) ; Bisphosphonates
  • Indications Back pain; Male osteoporosis; Osteoporosis
  • Focus Biomarker; Therapeutic Use
  • Acronyms BP-MUSASHI
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 Sep 2014 Primary endpoint (Hip bone mineral density) has not been met, as per the results published in the Osteoporosis International.
    • 08 Oct 2013 Results reporting patient preference and treatment adherence presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
    • 08 Oct 2013 Effects of treatment on back pain and tolerability (gastrointestinal symptoms) presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top